Last reviewed · How we verify
Perfluorocarbon
Perfluorocarbon is a Small molecule drug developed by Chinese PLA General Hospital. It is currently in Phase 2 development.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Perfluorocarbon |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Influence of Tamponade on Retinal Shift in Eyes Undergoing Vitrectomy for Rhegmatogenous Retinal Detachment: A Comparison of Gas Versus Silicone Oil in a Pakistani Population (NA)
- Efficacy and Safety of Myopic Macular Hole Closure Surgery Without Endotamponade Agent (NA)
- Study of Oxycyte in Severe Closed Head Injury (PHASE2)
- Autologous Tenon's Capsule Graft for Refractory Macular Holes (NA)
- PFAS Exposure and Immune Response to Vaccination in Adults (PHASE4)
- Pharmacokinetics, Safety, and Lung Deposition of 99mTc-DTPA Delivered Via the EDDIS System in Healthy Volunteers (PHASE1)
- No Endotamponade for Macular Hole Repair: the NEMAR Study (NA)
- Pars Plana Vitrectomy and Influence of Perfluorocarbon Liquids on Retinal Displacement (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perfluorocarbon CI brief — competitive landscape report
- Perfluorocarbon updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI
Frequently asked questions about Perfluorocarbon
What is Perfluorocarbon?
Who makes Perfluorocarbon?
What development phase is Perfluorocarbon in?
Related
- Manufacturer: Chinese PLA General Hospital — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing